Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06980636) titled 'A Trial of Shengmai Liquid for Long COVID Fatigue' on May 18.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Beijing University of Chinese Medicine
Condition:
Long COVID Fatigue
Intervention:
Drug: Shengmai Liquid
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: June 1, 2025
Target Sample Size: 100
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06980636
Disclaimer: Curated by HT Sy...